scholarly journals A Novel Just-In-Time-Online-Training for Nasopharyngeal Swab Specimen Collection During the COVID-19 Pandemic

Cureus ◽  
2021 ◽  
Author(s):  
Asit Misra ◽  
Kristy J Carlson ◽  
Christie A Barnes ◽  
Samuel K Pate ◽  
Benjamin B Stobbe ◽  
...  
2009 ◽  
Vol 64B (Supplement 1) ◽  
pp. i106-i118 ◽  
Author(s):  
S. T. Lindau ◽  
J. N. Hoffmann ◽  
K. Lundeen ◽  
A. Jaszczak ◽  
M. K. McClintock ◽  
...  

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1535-1535 ◽  
Author(s):  
S. M. Love ◽  
D. Mills ◽  
E. Eraklis ◽  
M. Hurlbert

1535 Background: One of the barriers to finding the cause of breast cancer is the difficulty basic scientists have in involving healthy women and obtaining human tissues, fluids, and information processed according to their needs. The Dr. Susan Love Research Foundation has collaborated with basic scientists successfully recruiting community women for studies. These efforts led to the Love/Avon Army of Women (AOW), a new “just in time” resource seeking to partner women with scientists to find the cause and prevention of breast cancer. Methods: The AOW is a pool of volunteers who have registered online ( www.armyofwomen.org ) that they are willing to participate in research. Peer-reviewed, funded projects submitted by researchers are reviewed by the AOW Scientific Advisory Committee for eligibility. An eBlast is sent to all AOW volunteers describing the study, and eligible women RSVP to the AOW for a secondary screen. The list is then sent to the researcher. If needed, referrals are made to a regional AOW Center for specimen collection, processing, and shipment. All scientists participate in a webcast with the eligible volunteers to explain the research before the study and describe the overall results at the end, ensuring a partnership between the women and the investigators. Results: AOW recruitment was initiated October 1, 2008, by Dr. Love on national media with the goal of creating a resource of 1,000,000 women available for researchers. To date over 260,000 women have joined. All ethnicities, ages (18–89), and states are represented. The first eBlast was sent out in mid-October for the Sister Study to accrue the last 5,000 women needed from diverse backgrounds. In 48 hours, 1,600 women had responded and qualified, and in 2 months, 2,500 had signed up with a 90% enrollment rate. The second study required women who were breastfeeding and scheduled for a breast biopsy. In one week, 30 eligible women were identified. Conclusions: The Love/Avon Army of Women is a just in time resource for breast cancer scientists to obtain exactly the specimens: breast or adipose tissue, ductal fluid, urine, saliva, blood, or information processed exactly as needed. This new partnership between women and scientists promises to revolutionize research and accelerate efforts to find the cause and prevention of breast cancer. No significant financial relationships to disclose.


Author(s):  
Jeffrey D Klausner ◽  
Noah Kojima ◽  
Susan M. Butler-Wu

The US Food and Drug Administration currently uses the nasopharyngeal swab specimen as the reference standard for evaluation of SARS-CoV-2 assays. We propose that the patient-infected status algorithm is a superior way to classify whether an individual is infected or not infected.


2020 ◽  
Vol 2 (1) ◽  
Author(s):  
Şahin Bayram ◽  
Aytuluk Hande Gürbüz

2021 ◽  
Vol 14 (12) ◽  
pp. e246884
Author(s):  
Victor Carvalho ◽  
Paula H Damasco ◽  
Thiago S Mello ◽  
Bruno Gonçalves

A 21-year-old woman arrived at the emergency department with dyspnoea, arterial hypotension and abdominal pain after 5 days with a influenza-like syndrome. SARS-CoV-2 was detected by reverse transcription PCR in a nasopharyngeal swab specimen. CT of the chest and abdomen with contrast demonstrated a minimal amount of free intraperitoneal fluid, gallbladder with wall oedema, multiple para-aortic lymph node and interlobular septal thickening with ground glass opacities on the lungs. No pleural effusion or thromboembolism. Early broad-spectrum antibiotics, high-flow nasal cannula and norepinephrine were started. She was successfully treated with intravenous immunoglobulin and pulse corticosteroid therapy with methylprednisolone. The patient was discharged home with complete resolution of her symptoms and returned to her previous health status.


2020 ◽  
Vol 382 (22) ◽  
pp. e76 ◽  
Author(s):  
Francisco M. Marty ◽  
Kaiwen Chen ◽  
Kelly A. Verrill

2020 ◽  
Vol 58 (8) ◽  
Author(s):  
Nicholas M. Moore ◽  
Haiying Li ◽  
Debra Schejbal ◽  
Jennifer Lindsley ◽  
Mary K. Hayden

ABSTRACT We compared the ability of 2 commercial molecular amplification assays (RealTime SARS-CoV-2 on the m2000 [abbreviated ACOV; Abbott] and ID Now COVID-19 [abbreviated IDNOW; Abbott]) and a laboratory-developed test (modified CDC 2019-nCoV reverse transcriptase PCR [RT-PCR] assay with RNA extraction by eMag [bioMérieux] and amplification on QuantStudio 6 or ABI 7500 real-time PCR system [abbreviated CDC COV]) to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in upper respiratory tract specimens. Discrepant results were adjudicated by medical record review. A total of 200 nasopharyngeal swab specimens in viral transport medium (VTM) were collected from symptomatic patients between 27 March and 9 April 2020. Results were concordant for 167 specimens (83.5% overall agreement), including 94 positive and 73 negative specimens. The ACOV assay yielded 33 additional positive results, 25 of which were also positive by the CDC COV assay but not by the IDNOW assay. In a follow-up evaluation, 97 patients for whom a dry nasal swab specimen yielded negative results by IDNOW had a paired nasopharyngeal swab specimen collected in VTM and tested by the ACOV assay; SARS-CoV-2 RNA was detected in 13 (13.4%) of these specimens. Medical record review deemed all discrepant results to be true positives. The IDNOW test was the easiest to perform and provided a result in the shortest time but detected fewer cases of COVID-19. The ACOV assay detected more cases of COVID-19 than the CDC COV or IDNOW assays.


2019 ◽  
Vol 9 (2) ◽  
pp. 134-141 ◽  
Author(s):  
Beate Zoch-Lesniak ◽  
Robert S Ware ◽  
Keith Grimwood ◽  
Stephen B Lambert

Abstract Background Most acute respiratory infection (ARI) research focuses on severe disease and overlooks the burden of community-managed illness. For community-based studies, home-based specimen collection by parents could be a resource-saving alternative to collection by healthcare workers (HCWs). In this study, we compared parent and HCW groups for their likelihood to collect specimens and the timeliness and quality of such collection. Methods In this unblinded randomized controlled trial, parents from Brisbane, Australia, were taught to identify new ARI episodes in their children aged <2 years. When their child had a new ARI, parents either collected a nasal swab from the child (P group) or contacted an HCW who visited to obtain a nasopharyngeal swab (HCW group). We compared the likelihood and timeliness of specimen collection and respiratory pathogen detection. A nested diagnostic study compared paired specimen collections from children in the HCW group. Results Included were 76 incident ARI episodes from 31 children and 102 episodes from 33 children in the P and HCW groups, respectively. The proportions of ARIs for which a specimen was collected were similar (P group, 69.7%; HCW group, 72.5%; P = .77), and pathogens were detected in 93.8% and 77.5% of the specimens, respectively (P = .03). The period between ARI onset and specimen collection was shorter in the P group than in the HCW group (mean difference, 1.9 days [95% confidence interval, 0.7–3.0 days]; P < .001). For the 69 paired specimens, viral loads were lower in the parent-collected swabs (mean cycle threshold difference, 4.5 [95% confidence interval, 3.1–5.9]; P < .001). Conclusions Parents and HCWs obtained samples in similar proportions of ARI episodes, but the parents collected the samples fewer days after ARI onset and with a resulting higher likelihood of pathogen identification. This method can be used in population-based epidemiological studies of ARI as a resource-saving alternative. Trial Registration ClinicalTrials.gov identifier NCT00966069.


2020 ◽  
Vol 9 (27) ◽  
Author(s):  
Sanaâ Lemriss ◽  
Amal Souiri ◽  
Narjis Amar ◽  
Nabil Lemzaoui ◽  
Omar Mestoui ◽  
...  

ABSTRACT Here, we report a complete genome sequence obtained for a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain isolated from a nasopharyngeal swab specimen of a Moroccan patient with coronavirus disease 2019 (COVID-19).


Sign in / Sign up

Export Citation Format

Share Document